As part of AstraZeneca’s Accelerate Change Together (ACT) on CKD programme to drive chronic kidney disease (CKD) change across the healthcare ecosystem, the Inside CKD project stream projected the clinical and economic burden of CKD from 2022 to 2027 across 31 countries and regions. The results have recently been compiled into a comprehensive portal on the Inside CKD website.
What is the Inside CKD project?
CKD is estimated to impact 8–16% of the global population [1,2,3], with prevalence having increased by nearly 30% between 1990 and 2017 [1]. Despite its prevalence, early-stage CKD is often undiagnosed and untreated, facilitating disease progression that can ultimately lead to complications, reduced quality of life, and significant economic strain.
The Inside CKD stream of the ACT on CKD programme focused on projecting the clinical and economic impacts of CKD from 2022 to 2027 across 31 countries and regions, using HealthLumen’s peer-reviewed and extensively validated microsimulation-based computer model.
Key aims of the Inside CKD online portal
The online portal is an interactive platform designed to help users easily explore the results of the Inside CKD project. It serves as a powerful resource for those working to address the growing CKD crisis through policy change, offering clear insights into how CKD burden is expected to worsen if no interventions take place and enabling stakeholders to anticipate and prepare for future challenges.
The portal includes:
- Key findings: Projections of the CKD clinical and economic burden across the 31 study countries and regions from 2022 to 2027.
- Interactive tools: Data trends across countries to inform decision-making.
- Research insights: Methodologies that underpin the project, all from one user-friendly platform.
- Publications: Access to the key peer-reviewed publications arising from the programme.
Some key results at a glance:
- Rising prevalence: From 2022 to 2027, CKD cases are projected to increase by 5.8% across the 31 counties studied, reaching 436.6 million people. 80% of these cases are projected to be undiagnosed.
- Rising healthcare costs: Annual direct healthcare costs of CKD and kidney replacement therapy (KRT) are expected to grow by 9.3% across the 31 counties studied, reaching a total cost of $406.7 billion by 2027.
- Disproportionate economic burden from late-stage disease: Although patients requiring KRT represent just 5.3% of the CKD population, they account for nearly 46% of total costs – highlighting the importance of early CKD diagnosis and management to prevent progression.
- Disease complications: Without intervention, it is projected that a significant number of heart failure (8,859), myocardial infarction (10,244), and stroke (7,797) complications will arise per 100,000 CKD patients across the 31 countries by 2027.
The Inside CKD online portal can help to empower stakeholders to shape policies and interventions that can transform CKD care worldwide. Visit insideckd.com today to explore the data.
References: